The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.

This workbook contains useful self-help tools and concepts to strengthen recovery from the misuse of stimulants. The workbook is designed as a pocket-size journal with space to record ideas and reminders about relapse triggers, mooring lines, and reasons for staying abstinent.

Gives patients information on buprenorphine and medication-assisted treatment for opioid addiction. Describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.

Esta hoja de hechos ofrece informacion a los pacientes sobre la buprenorfina y los tratamientos con ayuda de medicamentos para tratar el trastorno por uso de opioides, y tambien describe el mal uso y los sintomas del sindrome de abstinencia. Explica como funciona la buprenorfina, su uso apropiado, sus efectos secundarios y como se la utiliza en conjunto con al consejeria en el proceso de recuperacion.